InflaRx’s (IFRX) “Buy” Rating Reiterated at HC Wainwright

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $8.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 257.14% from the stock’s current price.

InflaRx Stock Up 5.2 %

Shares of IFRX opened at $2.24 on Friday. InflaRx has a twelve month low of $1.16 and a twelve month high of $2.82. The stock has a market cap of $131.90 million, a PE ratio of -2.07 and a beta of 1.67. The business’s 50-day moving average price is $1.93 and its 200-day moving average price is $1.67.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.